Research institution
University Hospital, Lille Clinical Trials
Studies where University Hospital, Lille is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 140Multiple Sclerosis
Switch to Ofatumumab and Level of Immunoglobulins
This real-life study aims to describe IgG levels after switching from ocrelizumab 600 mg IV every 6 to 8 months in Patients with Multiple Sclerosis (PwMS) to ofatumumab 20 mg SC every month and showing a decreasing level of IgG…
- Trial name
- SOLI (NCT07625800)
- Testing
- ofatumumab
- Where
- France
- Volunteers
- 115 people
- Sponsor
- University Hospital, Lille
Hepatocellular Carcinoma
Neoadjuvant Hypofractionated Stereotactic Body Radiation Therapy Prior to Surgery for Hepatocellular Carcinoma: a Feasibility Study.
Hepatocellular carcinoma (HCC) is the fifth more common cancer in the world, with high mortality rates, due to the low number of patients who are eligible for therapy with curative intent, like surgical resection.
- Trial name
- KARCHER-1 (NCT04587739)
- Testing
- Surgery with Neoadjuvant stereotactic body radiation therapy
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Lille
Breast Cancer, Liver Cancer
Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers
The European Society for Medical Oncology (ESMO) strongly recommends to develop multigene sequencing in the framework of molecular screening programmes, in order to improve access to innovative drugs and to accelerate clinical…
- Conditions
- Breast Cancer, Liver Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- ESCAT (NCT06958224)
- Testing
- Large and early multigene sequencing
- Where
- France
- Volunteers
- 360 people
- Sponsor
- University Hospital, Lille
Critically-ill Patients
Immunosuppression and Intensive Care Unit-acquired Multidrug-resistant Bacteria
Antimicrobial resistance AMR is an emerging global threat to human health, and intensive care units (ICUs) are a 'hot spot' for the emergence and diffusion of multidrug-resistant (MDR) bacteria.
- Trial name
- TANGERINE (NCT06652126)
- Testing
- Microbiological examinations.
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Lille
Endometriosis, Chronic Pain
Perioperative Yoga Therapy and Endometriosis Surgery
YOGENDOCHIR is a multicentre, prospective, randomised, controlled, parallel-group study involving 188 adult women scheduled to undergo surgery for endometriosis.
- Conditions
- Endometriosis, Chronic Pain, Impairment of Quality of Life
- Trial name
- YOGENDOCHIR (NCT07765680)
- Testing
- Standard surgical management for endometriosis, Structured perioperative yogatherapy programme plus standard surgical management
- Where
- 4 sites in France
- Volunteers
- 188 people
- Sponsor
- University Hospital, Lille
Schizophrenia, Hallucinations, Auditory
fMRI-based Neurofeedback to Relieve Drug-resistant Auditory Hallucinations
The INTRUDE trial aims at assessing the efficacy of an fMRI-based neurofeedback procedure on drug-resistant auditory hallucinations.
- Conditions
- Schizophrenia, Hallucinations, Auditory, Hallucinations, Visual
- Trial name
- INTRUDE (NCT04798131)
- Testing
- Active neurofeedback procedure
- Where
- France
- Volunteers
- 84 people
- Sponsor
- University Hospital, Lille
Hypersensitivity, Food, Legumes Allergy
Observational Study of IgE-Mediated Leguminous Allergies in a Pediatric Population
Prospective, monocentric, observational study with standard care follow-up during 5 years or until the patient reaches the age of 18.
- Trial name
- FabALL (NCT07811141)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Lille
Glioblastoma
Impact of Fluorescence-Guided Resection and Chemoradiotherapy on the Systemic Immune Response in Glioblastoma: A Kinetic Analysis of Immune Biomarkers.
The immune system plays a critical role in cancer progression and antitumor responses. Glioblastoma is an aggressive and incurable brain tumor characterized by a highly immunosuppressive microenvironment.
- Trial name
- SHAM INDYGO/DO (NCT07568782)
- Testing
- Fluorescence-guided resection (FGR)
- Where
- France
- Volunteers
- 17 people
- Sponsor
- University Hospital, Lille
Cardiogenic Shock, Extracorporeal Membrane Oxygenation
Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO
This multicenter randomized controlled trial compare two transfusion strategies of red blood cells transfusion in patients supported by veno-arterial extracorporeal membrane oxygenation for refractory cardiogenic shock.
- Conditions
- Cardiogenic Shock, Extracorporeal Membrane Oxygenation, Transfusion Related Complication, Anemia
- Trial name
- ICONE (NCT05699005)
- Testing
- Packed Red Blood Cells (PRBCs)
- Where
- 4 sites in France
- Volunteers
- 236 people
- Sponsor
- University Hospital, Lille
Esophageal Cancer, Esophagectomy
PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies
Esophageal cancer ranks as the seventh leading cause of cancer globally, with 604,100 new cases, and the sixth leading cause of cancer-related deaths worldwide.
- Conditions
- Esophageal Cancer, Esophagectomy, Multimodal Analgesia, Minimally Invasive Surgery
- Trial name
- PACEMIE (NCT07434739)
- Testing
- paravertebral catheter analgesia, Epidural group
- Where
- France
- Volunteers
- 506 people
- Sponsor
- University Hospital, Lille
Completed, with results posted
All 1Type 1 Diabetes, Hypoglycemia
Islet Allotransplantation With Steroid Free Immunosuppression
The restoration of endogenous insulin secretion carries significant hopes for shifting the paradigm of life long exogenous insulin therapy in selected groups of patients with type 1 diabetes(T1D).
- Conditions
- Type 1 Diabetes, Hypoglycemia, Metabolic Diseases
- Trial name
- NCT00446264
- Testing
- islet transplantation, daclizumab - sirolimus - tacrolimus
- Where
- France
- Volunteers
- 14 people
- Sponsor
- University Hospital, Lille